NOVARTIS AG
Last · —$146.88+4.47 (+3.14%)live · yahoo · 2s ago
Market cap$287.77B—
P/E · TTM22.2fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
Loading chart…
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$2.24
Est. revenue
14.7B
Earnings transcripts
- Issuer webcastAudio
Download the podcast (MP3 33 MB)
NOVARTIS AG
- Issuer webcastAudio
Download the podcast (MP3 35 MB)
NOVARTIS AG
- Issuer webcastAudio
Download the podcast (MP3 30 MB)
NOVARTIS AG
- Issuer webcastAudio
Download the podcast (MP3 34 MB)
NOVARTIS AG
- Issuer webcastAudio
Download the podcast (MP3 45 MB)
NOVARTIS AG
- Issuer webcastVideo
Presentation Recording
NOVUS HOLDINGS LIMITED
Press & signals
- GlobeNewswire
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
- GlobeNewswire
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
- Satelight
Medicines run short in Iran under US sanctions
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags